Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $63.88

Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have received a consensus recommendation of "Buy" from the ten analysts that are presently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $63.88.

CGON has been the subject of several analyst reports. Morgan Stanley reissued an "overweight" rating and issued a $55.00 price target on shares of CG Oncology in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research note on Friday, January 10th. TD Cowen initiated coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Remove Ads

Institutional Investors Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of CGON. GF Fund Management CO. LTD. acquired a new stake in CG Oncology during the 4th quarter worth $41,000. Amalgamated Bank raised its stake in CG Oncology by 107.6% during the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company's stock worth $61,000 after acquiring an additional 840 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in CG Oncology during the 4th quarter worth $68,000. KLP Kapitalforvaltning AS acquired a new stake in CG Oncology during the 4th quarter worth $100,000. Finally, Federated Hermes Inc. acquired a new stake in CG Oncology during the 4th quarter worth $172,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

CG Oncology Stock Down 0.7 %

CGON stock traded down $0.19 during mid-day trading on Friday, reaching $27.48. The company's stock had a trading volume of 512,900 shares, compared to its average volume of 627,223. CG Oncology has a fifty-two week low of $23.91 and a fifty-two week high of $46.99. The company's 50 day moving average is $28.32 and its two-hundred day moving average is $32.40.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.